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A report on the biannual Swiss Institute for Experimental
Cancer Research (ISREC) Symposium on the Cell and
Molecular Biology of Cancer, Lausanne, Switzerland, 19-22
January 2005. 
Every two years, biologists and oncologists gather in Lau-
sanne, on the shores of Lake Geneva, to discuss the latest
advances in research into the cell and molecular biology of
cancer. Presentations at the most recent of these meetings
covered a wide range of topics, a small selection of which is
described here. 
Several talks were devoted to the cellular protein degradation
machinery and its targets in the cell cycle. The protein p27 is
an inhibitor of the kinase activity of the complex of cyclin-
dependent kinase Cdk2 and cyclin E, and the destruction of
p27 is normally required before a cell can enter S phase of the
cell cycle. An essential role in p27 degradation has been
assigned to the E3 ubiquitin ligase SCF-Skp2 (named after its
components skp1, cullin and F-box protein). Willy Krek (Eid-
genössische Technische Hochschule, Zürich, Switzerland)
confirmed the importance of Skp2 in p27 degradation but
presented the audience with a new ubiquitin-ligase partner
for Skp2, a RING-domain containing protein called SAR1
(Skp2-associated RBCC protein 1) that belongs to the RBCC
(ring finger, B box, coiled-coil) family. Both SAR1 and Skp2
are found in a complex with Cul1 (a core subunit also found in
SCF) and the whole complex has been baptized CRF-Skp2
(for Cul1-RBCC-F-box complex containing Skp2). Specific
inhibition of CRF-Skp2 results in accumulation of p27, in
particular of the form phosphorylated on threonine 187, and
in a slowdown in G1 phase. Krek proposes that CRF-Skp2
might be the real culprit in p27 degradation, and that SCF-
Skp2 plays no role in this process - a suggestion that will be
bound to create a stir in the cell-cycle field.
However it happens, the degradation of p27 clears the path
for entry into S phase, in which the cell is confronted with
the task of replicating its DNA. Matthias Peter (Eidgenössis-
che Technische Hochschule) stressed the role of ubiquitina-
tion in this process also. Cells of budding yeast
(Saccharomyces cerevisiae) lacking Rtt101p, a relative of the
E3 ubiquitin-ligase components Cul3 and Cul4, display a
delay in the metaphase-to-anaphase transition of mitosis
and show increased sensitivity to genotoxic drugs. These
problems can be traced back to a defect in replicating certain
regions of the genome - ‘slow zones’ - which include the
rRNA locus. In these areas, Rtt101p appears to be required
for the restart of collapsed replication forks (but not of the
ones that have only stalled but are still intact), suggesting a
role for ubiquitination and possibly protein degradation in
this process. 
Ubiquitination does not always result in protein degrada-
tion. Martin Eilers (University of Marburg, Germany)
described work on the ubiquitination of the transcription
factor and proto-oncogene c-Myc. In contrast to known
ubiquitinations of c-Myc, Eilers reported that ubiquitination
by the E3 enzyme Hect H9 does not affect c-Myc stability.
Instead, ubiquitination of lysine residues within, and close
to, the nuclear localization signal enhance c-Myc’s affinity
for the transcriptional coactivator p300. This activity of Hect
H9 is inhibited by the transcriptional activator Miz1, which
in turn is inhibited by binding to c-Myc. From these observa-
tions, Eilers proposed a model  in which Hect H9 plays an
important role in switching Myc’s role from a transcriptional
repressor (when in the Myc:Miz1 complex) to an activator
(when Myc is bound directly to its binding sites in DNA).
Like Myc, the insulin signaling pathway plays an essential
role in controlling cellular growth during development. Ernst
Hafen (University of Zürich, Switzerland) reported how his
group has used genetic screens in Drosophila melanogaster
to identify novel components of this pathway. One of these,
named Susi, binds to and inhibits the regulatory subunit of
phosphatidylinositol 3-OH kinase (PI 3-kinase), and thus
acts as a negative regulator of growth. Susi has no apparent
ortholog in vertebrates, in contrast to two other cell-growthinhibitors  discovered by these screens, the paralogous pro-
teins Scylla and Charybdis. These two function in the insulin
pathway downstream of PI 3-kinase and the protein kinase
(and certified proto-oncogene) Akt/PKB and upstream of
the tumor suppressors TSC1 and TSC2, resulting in the inhi-
bition of the kinase Tor (target of rapamycin) and of down-
stream effectors such as ribosomal protein S6 kinase, thus
suppressing cell growth. 
Transcription of the Scylla and Charybdis genes is  induced
by hypoxia via the hypoxia-inducible transcription factor
HIF. The same induction by HIF and downstream effects on
TSC1/TSC2 was reported for the vertebrate counterparts of
Scylla and Charybdis, Redd1/Rtp801, by James Brugarolas
of Bill Kaelin’s group (Harvard Medical School, Boston,
USA). Thus, this protein family appears to lie at the intersec-
tion of two important and evolutionarily conserved signaling
pathways, the hypoxia-induced and the insulin pathway.
Turning from the control of size to the control of develop-
mental fate, several speakers discussed molecular compo-
nents of the Wnt signaling pathways, which have roles in
both development and disease. Konrad Basler (University of
Zürich) reported work in Drosophila melanogaster showing
that the recently identified components Legless/Bcl-9 (Lgs)
and Pygopus (Pygo) do not exclusively serve to localize the
transcription factor β-catenin/Armadillo to the nucleus in
response to Wnt signaling, but also themselves have roles as
transcriptional coactivators. The relative importance of the
two proteins in Wnt signaling appears to be different, as
revealed by mouse embryos lacking either both Pygopus
paralogs (pygo1-/- pygo2-/-) or both Legless paralogs (lgs1-
/- lgs2-/-). Fabienne Murphy-Seiler, working with Michel
Aguet (ISREC, Epalinges, Switzerland), reported that
these mutant embryos die at different stages of embryonic
development (embryonic day (E) 10.5 for lgs1-/- lgs2-/-,
and E14.5 for pygo1-/- pygo2-/-). She also reported that
only Legless is required for the regeneration of adult
intestinal epithelium after damage, and that neither
Legless nor Pygopus seem to be essential for intestinal
epithelial homeostasis under normal conditions. As these
mutant phenotypes differ dramatically from those of
various Wnt mutants, it appears that non-canonical Wnt
signaling, which does not involve the downstream effector
TCF and its cofactors, plays an important role in many of
these processes.
Wnt signaling is an important player in colon cancer, but it
does not act alone. Hans Clevers (Netherlands Institute for
Developmental Biology, Utrecht, The Netherlands) showed
that Wnt cooperates with the cell-surface protein Notch to
maintain stem cells in colonic crypts, and that a similar coop-
eration might also take place in adenomas. In line with these
findings, inhibition of Notch signaling in such adenomas (by
interference with γ-secretase, which is required for cleavage
of Notch to liberate the active Notch-intracellular domain)
reduced their rate of proliferation and promoted differentia-
tion towards the goblet cell type. These results raise the
exciting possibility that γ-secretase drugs that were devel-
oped for Alzheimers’ disease might find a second life in the
treatment of colon cancers. 
A class of molecules that has attracted considerable general
attention lately is the microRNAs (miRNAs), short RNAs
involved in post-transcriptional regulation. Steven Cohen
(European Molecular Biology Laboratory, Heidelberg,
Germany) pointed to the widespread distribution of miRNA
loci in metazoan genomes and suggested that they might
control a substantial fraction of protein-coding genes. But
how important are these molecules for development? Alex
Schier (Skirball Institute of Biomolecular Medicine, New
York University School of Medicine, USA) has addressed this
question in zebrafish. His group created embryos that were
both zygotically and maternally mutant for Dicer, an enzyme
essential for the maturation of miRNAs. These embryos
lacked most (if not all) mature miRNAs, although microinjec-
tion of double-stranded RNA still resulted in gene silencing,
demonstrating that only the processing of the miRNAs is
impaired. Despite these defects, the mutant embryos under-
went a surprisingly normal development: axis formation,
regionalization and the activity of all major signaling path-
ways appeared normal. Some major defects were found in the
central nervous system (malformation of the ventricles and
problems with neuronal differentiation); these could be
partly overcome by injection of a specific class of miRNAs,
although the partially rescued embryos were still not able to
develop to term. These findings suggest that miRNAs do not
control the big decisions in development, but rather function
to fine-tune tissue homeostasis, or work as “micromanagers”
(as Schier called them).
The audience at this meeting was treated to a diversity of
presentations of high quality, and will undoubtedly be
looking forward to the next ISREC symposium in 2007.
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